Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 286

Results For "HR"

6014 News Found

North India’s first government homoeopathic college coming up in Kathua: Dr. Jitendra Singh
Policy | March 11, 2024

North India’s first government homoeopathic college coming up in Kathua: Dr. Jitendra Singh

The institution will be spread over an area of more than 8 acres


LVPEI observes World Glaucoma Week
Healthcare | March 11, 2024

LVPEI observes World Glaucoma Week

Vision loss due to Glaucoma can be prevented if it is detected and treated early


Women's integral role in India's US$ 5 trillion ambition
News | March 11, 2024

Women's integral role in India's US$ 5 trillion ambition

Women emerge as the cornerstone of this monumental undertaking


India approves Rs. 10,300 crore for AI Mission
Digitisation | March 08, 2024

India approves Rs. 10,300 crore for AI Mission

The investment will catalyse various components of the IndiaAI Mission


Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
Biotech | March 07, 2024

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years


EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
Drug Approval | March 07, 2024

EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process


Sakar's oncology unit receives EU GMP approval
Drug Approval | March 07, 2024

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters


Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme
Policy | March 07, 2024

Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme

The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics


BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends
Clinical Trials | March 06, 2024

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months


Strides receives USFDA approval for Gabapentin Tablets
Drug Approval | March 06, 2024

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty